FDA Approves First Blood Test for Alzheimer’s Diagnosis
Lumipulse G® test (Fujirebio Diagnostics) offers a less invasive and more accessible method to detect amyloid plaques in symptomatic patients.
Med.IQ
3 min read
June 11, 2025
Sources
- Food and Drug Administration. FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. Disponível em: .
Highlights
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
Written by Med.IQ
About
The first healthtech knowledge company in Latin America. We connect, create, and disseminate content with the purpose of driving change and fostering new future possibilities for doctors and patients. We enable educational solutions.